The purpose of this study is to investigate new therapies for advanced lung disease.
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: February 2020
This research study is being conducted to learn about the progression and cause of lung disease. By agreeing to be a part of this study, you will allow the lung tissue which would normally have been discarded after your procedure, to be used for research purposes to allow us to understand more about your condition which may potentially lead to novel treatments and therapeutics. For this study, the investigators will isolate specific cells from the lung tissue and measure cellular, molecular and genetic mechanisms responsible for regulating lung disease. No other type of research will be performed on these samples nor will the samples be given to other investigators for unrelated research.
- Other: novel biomarkers of lung disease
- we will be identifying molecular, genetic, and cellular markers of lung disease
Clinical Trial Outcome Measures
- The development of novel therapeutics for interstial lung disease
- Time Frame: 10 years
- Our research on these human lung cells will provide critical data which will aid in the diagnosis and treatment of a variety of different lung diseases, which have no cure.
Participating in This Clinical Trial
- any one on lung transplant list
- HIV positive
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Ohio State University
- Provider of Information About this Clinical Study
- Principal Investigator: Megan Ballinger, Research Asst Professor – Ohio State University
- Overall Official(s)
- Megan Ballinger, Principal Investigator, Ohio State University
- Overall Contact(s)
- Megan Ballinger, 614-292-6578, firstname.lastname@example.org
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.